Abstract
To clarify the role of p27/Kip1 (p27) in primary central nervous system lymphomas (PCNSLs), we examined p27 expression by immunohistochemical methods in a series of 22 patients with PCNSL. We attempted to correlate the expression of p27 with proliferation potential and prognosis. Although the MIB-1 labeling index (LI) was lower in tumors with low p27 expression (26.7% +/- 17.2% vs 38.1% +/- 16.3%), it was not significantly different from that of tumors with high p27 expression (P = 0.1253). Survival analysis revealed that high p27 expression was significantly associated with poorer overall prognosis (P = 0.0011); however, the MIB-1 LI were not associated with prognosis. Our results suggest p27 as a predictor of prognosis in patients with PCNSL.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor
-
Cell Nucleus / pathology
-
Central Nervous System Neoplasms / genetics*
-
Central Nervous System Neoplasms / pathology*
-
Central Nervous System Neoplasms / therapy
-
Coloring Agents
-
Cyclin-Dependent Kinase Inhibitor p27 / biosynthesis*
-
Cyclin-Dependent Kinase Inhibitor p27 / genetics*
-
Cyclophosphamide / therapeutic use
-
DNA-Binding Proteins / metabolism
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Immunohistochemistry
-
Kaplan-Meier Estimate
-
Lymphoma / genetics*
-
Lymphoma / pathology*
-
Lymphoma / therapy
-
Male
-
Middle Aged
-
Paraffin Embedding
-
Prednisone / therapeutic use
-
Prognosis
-
Tissue Fixation
-
Transcription Factors / metabolism
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Biomarkers, Tumor
-
Coloring Agents
-
DNA-Binding Proteins
-
Transcription Factors
-
Cyclin-Dependent Kinase Inhibitor p27
-
HIVEP2 protein, human
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone